Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries

European Journal of Health Economics

Volumn 15, Issue SUPPL. 1, 2014, Pages

  Brodszky, Valentin ^a   Baji, Petra ^a   Balogh, Orsolya ^a   Péntek, Márta ^a,b  

^a Institute of Entrepreneurship and Innovation   (Hungary)

^b Pest Megyei Flor Ferenc Korhaz   (Hungary)

Author keywords

Biosimilar pharmaceuticals; Budget impact analysis; Central and Eastern Europe; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; CT P 13; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; BUDGET; BULGARIA; COST CONTROL; CZECH REPUBLIC; DRUG COST; HUMAN; HUNGARY; MAJOR CLINICAL STUDY; POLAND; PRIORITY JOURNAL; REIMBURSEMENT; RHEUMATOID ARTHRITIS; ROMANIA; SLOVAKIA; ARTHRITIS, RHEUMATOID; COST; ECONOMICS; EUROPE; PROCEDURES; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BUDGETS; COST SAVINGS; COSTS AND COST ANALYSIS; DRUG COSTS; EUROPE; HUMANS; MODELS, ECONOMIC;

EID: 84904338227     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-014-0595-3     Document Type: Article

References (12)

1. Sokka, T., Kautiainen, H., Pincus, T., Verstappen, S.M., Aggarwal, A., Alten, R., Andersone, D., Badsha, H., Baecklund, E., Belmonte, M., Craig-Muller, J., da Mota, L.M., Dimic, A., Fathi, N.A., Ferraccioli, G., Fukuda, W., Geher, P., Gogus, F., Hajjaj-Hassouni, N., Hamoud, H., Haugeberg, G., Henrohn, D., Horslev-Petersen, K., Ionescu, R., Karateew, D., Kuuse, R., Laurindo, I.M., Lazovskis, J., Luukkainen, R., Mofti, A., Murphy, E., Nakajima, A., Oyoo, O., Pandya, S.C., Pohl, C., Predeteanu, D., Rexhepi, M., Rexhepi, S., Sharma, B., Shono, E., Sibilia, J., Sierakowski, S., Skopouli, F.N., Stropuviene, S., Toloza, S., Valter, I., Woolf, A., Yamanaka, H.: Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res. Ther. 12(2), R42 (2010). doi:10.1186/ar2951
2. Laires, P.A., Exposto, F., Mesquita, R., Martins, A.P., Cunha-Miranda, L., Fonseca, J.E.: Patients' access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries. Eur. J. Health Econ. 14 (6), 875-885 (2013). doi:10.1007/s10198-012-0432-5
3. Mauskopf, J.A., Sullivan, S.D., Annemans, L., Caro, J., Mullins, C.D., Nuijten, M., Orlewska, E., Watkins, J., Trueman, P.: Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices - budget impact analysis. Value Health 10(5), 336-347 (2007)
4. Orlewska, E., Gulacsi, L.: Budget-impact analyses: a critical review of published studies. PharmacoEconomics 27(10), 807-827 (2009)
5. van de Vooren, K., Duranti, S., Curto, A., Garattini, L.: A critical systematic review of budget impact analyses on drugs in the EU countries. Appl. Health Econ. Health Policy 12(1), 33-40 (2014). doi:10.1007/s40258-013-0064-7
6. Launois, R., Payet, S., Saidenberg-Kermanac'h, N., Francesconi, C., Franca, L.R., Boissier, M.C.: Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis. Joint Bone Spine 75(6), 688-695 (2008). doi:10.1016/j.jbspin.2008.04. 012
7. Sorensen, J., Andersen, L.S.: The case of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis. PharmacoEconomics 23(3), 289-298 (2005)
8. Tóthfalusi, L., Endrényi, L., Chow, S.-C.: Statistical and regulatory considerations in assessments of interchangeability of biological drug products. Eur. J. Health Econ. (2014). doi:10.1007/s10198-014-0589-1
9. Péntek, M., Poór, G., Wiland, P., Martina, O., Brzosko, M., Codrenau, C., Brodszky, N., Gulácsi, L.: Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. Eur. J. Health Econ. (2014). doi:10.1007/s10198-014-0592-6
10. Laki, J., Székelyné Mónok, G.: Biological treatments - analysis by the NHIFA. http://www.oep.hu/pls/portal/url/ITEM/ C97D04DF65C8B4CEE040A8C0CB324B94. (2012)
11. Koncz, T., Pentek, M., Brodszky, V., Érsek, K., Orlevska, E., Gulacsi, L.: Adherence to biologic DMARD therapies in rheumatoid arthritis. Expert Opin. Biol. Ther. 9, 1367-1378 (2010)
12. Laki, J., Monok, G., Palosi, M., Gajdacsi, J.Z.: Economical aspect of biological therapy in inflammatory conditions in Hungary. Expert Opin. Biol. Ther. 13(3), 327-337 (2013). doi:10.1517/14712598.2013.735654